Expression of CHK1 has been reported to be elevated in pancreatic cancer, and inhibitors targeting CHK1 have been shown to have clinical potential for treatment of pancreatic cancer [9, 14, 15]. Here, CHEK1 is linked to familial pancreatic carcinoma.